Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model-Reference-Cited by-同舟云学术

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

Published:2023-01-05 Issue:1 Volume:136 Page:102-104
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Chai Sanbao¹,Yu Shuqing²,Liu Fengqi²,Liu Zuoxiang²,Yang Qingqing²,Sun Feng²

Affiliation:

1. Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China

2. Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing 100191, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference7 articles.

1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

2. Effects of incretin-based therapies on weight-related indicators among patients with type 2 diabetes: a network meta-analysis;Xu;Biomed Environ Sci,2020

3. Neurological manifestation of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis;Gao;Aging Dis,2019

4. Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs – a systematic literature review. Next steps in methodology development?;Baran-Kooiker;Front Public Health,2018

5. Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps;Frazão;BMC Med Inform Decis Mak,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance;Journal of Diabetes and its Complications;2023-08